COG Cambridge Cognition Holdings Plc

TIDMCOG

RNS Number : 2125T

Cambridge Cognition Holdings PLC

21 July 2022

21 July 2022

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Trading Update and Notice of Results

Continued strong growth and outlook with revenue increased by 31% on prior year

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce strong growth for the six months ended 30 June 2022.

The unaudited financial highlights for the six months ended 30 June 2022 are:

-- Increase in like-for-like sales orders of 44% to GBP7.2 million (H1 2021: GBP8.6 million including GBP3.6 million of one-off orders)

   --          Growth in revenue of 31% to GBP5.9 million (H1 2021: GBP4.5 million) 

-- Increase in contracted order book of GBP1.5m million since the last year end to GBP18.6 million (31 December 2021: GBP17.1 million)

   --          Profit after tax in line with expectations at GBP0.02 million (H1 2021: GBP0.1 million) 

-- Continued growth in cash balances at 30 June 2022 to GBP8.6 million (31 December 2021: GBP6.8 million)

The Company followed up its strong performance in 2021 with a considerable growth in revenues to GBP5.9 million in the first half of 2022, which is up 31% on H1 2021 (H1 2021: GBP4.5 million). Order intake was in line with the Board's expectations at GBP7.2 million, up 44% on a like-for-like basis on H1 2021 (H1 2021: GBP8.6 million including GBP3.6 million of one-off orders) and the Company has a healthy and growing qualified pipeline of opportunities for the second half of 2022.

The contracted order book was GBP18.6 million at 30 June 2022, an increase of GBP1.5 million since the start of the year. The order book provides the Company with visibility over future revenues and provides a solid foundation from which the Company can continue with its plans to invest in product and commercial development to further expand the business.

Trading conditions continue to be positive and the Company has high levels of engagement with existing and potential new clients. With continued investment in commercial activities and product development, the Company expects to achieve further year-on-year revenue growth. The cash position continues to grow to GBP8.6 million at 30 June 2022 and provides the business with the platform to make considered investments as opportunities arise.

Notice of Results

The interim results for the six months ended 30 June 2022 will be announced on 20 September 2022.

The Company will conduct a live presentation and Q&A session for investors on the same day at 5:30 pm BST. The presentation is open to all existing and potential shareholders. Those wishing to attend should email cog@investor-focus.co.uk and they will be provided with log in details. There will be the opportunity for participants to ask questions at the end of the presentation. Questions can also be emailed to the above address ahead of the presentation.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information, please contact:

 
 Cambridge Cognition Holdings Plc                 Tel: 01223 810 700 
 Matthew Stork, Chief Executive Officer             press@camcog.com 
 Stephen Symonds, Chief Financial Officer 
 
 Panmure Gordon (UK) Ltd 
  (NOMAD and Joint Broker)                         Tel: 020 78862500 
 Freddy Crossley / Emma Earl / Mark             (Corporate Advisory) 
  Rodgers 
 Rupert Dearden                                  (Corporate Broking) 
 
 Dowgate Capital Limited (Joint Broker)           Tel: 020 3903 7715 
 David Poutney / James Serjeant 
 
 IFC Advisory Ltd (Financial PR and               Tel: 020 3934 6630 
  IR) 
 Tim Metcalfe / Graham Herring / Zach       cog@investor-focus.co.uk 
  Cohen 
 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTVBLFLLDLFBBZ

(END) Dow Jones Newswires

July 21, 2022 02:00 ET (06:00 GMT)

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De May 2023 a May 2024